Prolonging the Effects of Factor IX Replacement Therapy in Hemophilia B
Introduction/Overview
Introduction/Overview (cont)
Importance of Prophylaxis, and Limitations on Its Application, in Hemophilia B
Key Unmet Need in Hemophilia B: Reducing Patient Burden of Disease
Improving Adherence in Hemophilia B
Potential Barriers to Adherence in Hemophilia Prophylaxis
Improving Adherence by Addressing the Barriers to Prophylaxis
Surgical Experience With EHL rFIX Replacement Therapy
Annualized Bleeding Rates: Results From the B-LONG Study
Inhibitor Development in EHL Molecules for Treatment of Hemophilia B
Annualized Bleeding Rates: Results From the Nonacog Beta Pegol Phase 3 Trial
The Importance of Maintaining Trough Levels to Prevent Breakthrough Bleeding
EHL Agents and Treatment Individualization
rFIX-FP Phase 3 Study in Hemophilia B: Study Design
rFIX-FP Phase 3 Study: AsBRs of Prophylaxis Patients
rFIX-FP Phase 3 Study: Safety Results
EHL Agents and Treatment Individualization
Phenotypic Variability Among PWH
Pharmacokinetic Characteristics of 3 EHL Agents
Evolution of FVIII/FIX Concentrates
Case Studies With Long-Acting FIX Therapies
Introduction/Overview
Case 1: 30-Year-Old Man Typically Treated on Demand
Case 2: Older Man With a Sedentary Lifestyle
Case 3: Patient Requiring Surgery
Case 4: Patient With a Frequent Bleeding Phenotype
Summary and Conclusions
Hemophilia B Treatment Goals
The Benefits of EHL Therapies in Hemophilia B
Transforming the Treatment Paradigm
Abbreviations
Abbreviations (cont)
Abbreviations (cont)